Brain 17 Vienna
Targeted therapy
• Bevacizumab
=> probably no need to cross the BBB
• EGFR inhibitors (erlotinib, gefitinib…) => only in patients with sensitizing EGFR mutation
• ALK inhibitors (crizotinib, ceritinib…)
=> only in patients with EML4-ALK translocation
Made with FlippingBook - Online catalogs